{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-23-000072","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.385963+00:00","generated_at":"2026-06-09T05:24:35.967447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine Q3 INGREZZA sales $486M (+29% YoY); raises 2023 guidance to $1.82-1.84B","bullets":["INGREZZA Q3 net sales $486M (+29% YoY); total product sales $492M.","GAAP EPS $0.82; non-GAAP EPS $1.54. Cash & securities $1.55B.","INGREZZA 2023 net sales guidance raised to $1.82-1.84B.","FDA approved INGREZZA for Huntington's chorea; NDA accepted for oral granules (PDUFA Apr 30, 2024).","Phase 3 crinecerfont met primary endpoints in adult and pediatric CAH; Analyst Day Dec 5."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-23-000072","json":"https://secwatch.observer/filing/0000914475-23-000072.json","markdown":"https://secwatch.observer/filing/0000914475-23-000072.md","text":"https://secwatch.observer/filing/0000914475-23-000072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/nbix-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:24:35.967447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18d05c219bbb7df06cddc220e46064ea28ca7580","claim":"NEUROCRINE BIOSCIENCES INC updated its the third quarter ended September 30, 2023 guidance (raised).","evidence_excerpt":"On October 31, 2023, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000091447523000072/0000914475-23-000072-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}